Kynam Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Kynam Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-28,696	Closed	-$1.03M	–	34
2023 Q1	$1.03M	Sell	28,696 -191	-0.7%	-$7.06K	0.13%	30
2022 Q4	$1.14M	Buy	28,887 +95	+0.3%	+$3.46K	0.17%	28
2022 Q3	$1.04M	Sell	28,792 -146,208	-84%	-$5.26M	0.22%	29
2022 Q2	$5.32M	Sell	175,000 -308,270	-64%	-$9.32M	1.36%	18
2022 Q1	$14.8M	Sell	483,270 -186,823	-28%	-$5.59M	4.79%	7
2021 Q4	$20.9M	Buy	+670,093	New	+$20M	11.19%	2

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Kynam Capital Management's XENE Position: Q2 2023 in Review

Kynam Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2023, closing a stake of 28,696 shares — an estimated $1.03M sold.

Kynam Capital Management first reported a position in XENE in Q4 2021 and held it in 6 quarters. The position peaked at $20.9M in Q4 2021. 175 funds tracked by Wall St. Rank hold XENE as of Q2 2023.

Kynam Capital Management reported no remaining Xenon Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Kynam Capital Management sold 28,696 Xenon Pharmaceuticals shares in Q2 2023, an estimated $1.03M.
Kynam Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2021 and held it in 6 quarters.
Kynam Capital Management's Xenon Pharmaceuticals position peaked at $20.9M in Q4 2021.
175 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2023.

Based on Kynam Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.